January 18th, 2021 | 09:54 CET
Enapter, NEL ASA, Bayer - the future can begin!
Without a doubt, hydrogen will become one of the most important energy sources in the coming decades. According to a study by the Hydrogen Council, demand for hydrogen will increase eightfold by 2050. According to this study, hydrogen could account for one-fifth of global final energy consumption. Some listed stocks' valuations have already risen to dizzying heights due to the very optimistic forecasts for the future. In addition, a fierce battle for the best technologies and patents is going on at the moment. Some of the well-known companies will fall by the wayside, and new ones will move up.
time to read: 3 minutes | Author: Stefan Feulner
ISIN: DE000A255G02 , NO0010081235 , DE000BAY0017
Table of contents:
Author
Stefan Feulner
The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.
Tag cloud
Shares cloud
Made in Germany
Enapter AG is currently well-positioned in the market. The Company's vision is to use German technology to produce green hydrogen more cheaply than the competition. The Company wants to achieve this with its innovative Anion Exchange Membrane (AEM) electrolysis. With this technology, which is based on modularity, it is possible to produce electrolysers and stacks that can be scaled up to larger units more efficiently and cost-effectively. The software developed in-house by Enapter AG is another significant asset. The perfect combination with the powerful hardware results in a modern energy system. Many individual electrolyser or stack units form an extensive system and are controlled uniformly via the software. Enapter plans to mass-produce its electrolyser by 2022 at the latest. To do this, it plans to open a factory in North Rhine-Westphalia to produce up to 100,000 units a year.
Patents and technology give a head start
According to the Company's management, it has a technology lead over the competition of 3 to 5 years. The Company invests 6 to 8% of sales annually in research and development to build on this. Enapter has long-standing research collaborations with the Universities of Pisa, Madrid, and Munich's Technical University. Enapter also collaborates on various research projects with the German Aerospace Center (DLR), the Norwegian University of Science and Technology (NTNU), and the Jülich Research Center. In addition to its strong R&D work, the Company boasts a growing patent portfolio of approved and filed patents. The most crucial patent protects the core technology, AEM electrolysis with a dry cathode, in Europe, the USA, China and India. The market capitalization of Enapter AG is currently just under EUR 690 million.
Spaniards keep their word
In contrast to Enapter, NEl ASA currently produces much larger electrolysers. The main application area is centralized large industrial solutions. We reported on the preliminary agreement from Spain in early November, and the order has now been confirmed. NEL Hydrogen Electrolyser, a division of Norwegian hydrogen specialist NEL ASA, has received a EUR 13.5 million order from Spanish energy Company Iberdrola. The order is for a 20 MW PEM solution for a fertilizer project in Spain that will be supplied with green electricity. Iberdrola, one of the world's largest utilities, has launched a project with one of the world's leading fertilizer manufacturers, Fertiberia, to build the most extensive green hydrogen plant in Europe. In Puertollano, Spain, a 100 MW photovoltaic system, a battery system with a storage capacity of 20 MWh, and a 20 MW electrolyser are to be built. The hydrogen will be used mainly for the production of fertilizer.
Ready for the future
Currently, Bayer AG is doing everything it can to make the relatively modest year of 2020 a thing of the past. Despite the still pending settlement in the glyphosate lawsuit, the Leverkusen-based Company is eager to tap into new growth markets. A healthy boost is expected from gene and cell therapies in the coming years. Many pharmaceutical companies are intensively researching these therapies. They are intended to enable new therapeutic approaches for widespread diseases such as heart failure and provide cures for rare diseases rather than merely alleviating symptoms. In 2020, 25 collaborations were announced in this area, and 7 compounds are currently being developed.
The golden straw
The hottest topic currently is the collaboration and service agreement with CureVac, which was signed at the beginning of January. CureVac is researching the Corona vaccine CVnCoV, for which the pivotal Phase III clinical trial began in mid-December. CureVac expects initial results at the end of the first quarter of 2021. The pharmaceutical giant is entering the game through the back door. Now Bayer is considering starting the production of Corona vaccines. With its global production network, the pharmaceutical giant would undoubtedly be in a position to produce vaccines in larger quantities. In the event of approval of the CureVac vaccine, the EU Commission has already secured 405 million doses for the EU countries.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.
The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.
